前列腺素E1在慢性肾功能衰竭治疗中的应用

目的 观察前列腺素E1（PGE1）在慢性肾衰竭（CKD 2 ～4期）治疗中的临床应用效果.方法 选取CKD 2 ～4期患者128例,以随机数字表法分为观察组与对照组,每组各64例.对照组给予常规药物治疗,观察组在对照组的基础上增加PGE1,两组均治疗3个月.比较治疗前后的肾功能指标、治疗后临床疗效以及不良反应.结果 治疗前两组患者肾功能指标比较,差异均无统计学意义（t=0.27～0.95,P＞0.05）；治疗后,观察组与对照组24h尿蛋白定量（t=3.41,P＜0.05）、内生肌酐清除率（t=4.04,P＜0.05）、血清肌酐值（t =4.15,P＜0.05）、血清尿素氮（t=3.92,P＜0.05）指标比较,差异均具有统计学意义.观察组与对照组总有效率分别为84.37％、57.81％,差异有统计学意义（x2=5.63,P＜0.05）.观察组未见不良反应.结论 在目前尚缺乏特别有效治疗方法的情况下,前列腺素E1的应用可能在改善患者尿蛋白及肾功能方面起到一定的积极作用.

Application of prostaglandin E1 in treatment of patients with chronic renal failure

Objective To investigate the clinical effects of prostaglandin E1 （PGE1） in the treatment ot chronic renal failure in the 2nd ～ 4th period.Methods 128 patients with CKDs at stage 2 to 4 were selected and randomly divided into the observation group and control group,64 cases in each group.Patients in control group were given routine drug treatment,and patients in observation group were given PGE1 on the basis of the control group.They all treated for 3 months.Renal function indicators before and after treatment,curative effect and adverse reaction were compared.Results There were no statistical differences in renal function indicators before treatment in two groups （t =0.27 ～ 0.95,P 〉 0.05）.After treatment,the 24 hours urinary protein （t =3.41,P 〈 0.05）,creatinine clearance rate （t =4.04,P 〈 0.05）,serum creatinine （t =4.15,P 〈 0.05）,serum urea nitrogen （t =3.92,P 〈 0.05） between the two groups had statistical differences.Total effective rate of the observation group was 84.37%,which was significantly higher than 57.81% of the control group （x2 =5.63,P 〈 0.05）.There was no adverse reaction observed in observation group.Conclusion PGE1 might improve patients＆#39; proteinuria and renal function in the current situation of lacking effective treatment.